XBRANE BIOPHARMA PRESENTS THE NOMINATION COMMITTEE

According to the principles for the nomination committee in Xbrane Biopharma AB ("the Company" or "Xbrane") adopted at the Annual General Meeting on May 5, 2025, the nomination committee, appointed for the period until a new committee is designated, shall consist of three members, who are to be appointed by the Company's three largest shareholders by voting power as of September 30, 2025. The Chairman of the Board shall be an adjunct member when needed. If a shareholder does not exercise their right to appoint a member to the nomination committee, the next largest shareholder by voting power shall have the right to appoint a member.

Based on the above, the nomination committee ahead of the 2026 Annual General Meeting has been established to consist of the following individuals, who together represent approximately 26 percent of the shares and votes in the Company as of September 30, 2025:

1. Ashkan Pouya, utsedd av Systematic Group AB, the Company's largest shareholder
2. Carl-Åke Carlsson, utsedd av Six Rays Pte. Limited, the Company's second-largest shareholder
3. Bengt Göran Westman, the Company's third-largest shareholder
4. Anders Tullgren, Chairman of Xbrane's Board, adjunct member when needed

Ashkan Pouya has been appointed Chairman of the nomination committee.

The nomination committee's task is to, ahead of the Annual General Meeting, prepare and present proposals regarding Chairman of the Annual General Meeting, candidates for the position of Chairman and other members of the Board, Board fees and other compensation for board work for each board member, fees to members of board committees, election and remuneration of the Company's auditor, Principles for the nomination committee

The nomination committee's proposals will be presented in the notice to the 2026 Annual General Meeting and on the Company's website: www.xbrane.com.

Shareholders may submit proposals to the nomination committee ahead of the Annual General Meeting on May 5, 2026, until January 19, 2026. Proposals can be sent to:

Xbrane Biopharma AB Nomination Committee, c/o Xbrane Biopharma AB, Scheeles väg 5, 171 65 Solna, Sweden or via email: valberedning@xbrane.com

Xbrane's Annual General Meeting will be held in Solna on May 5, 2026.

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

XBRANE BIOPHARMA PRESENTS THE NOMINATION COMMITTEE